Emergent BioSolutions Inc.
EBSNYSEHealthcare● Active
$8.22
+$0.15(+1.86%)
Market Cap$424121600
P/E Ratio—
52W High$14.06
52W Low$5.62
Emergent BioSolutions Inc. (EBS) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · EBS · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.74B | $1.04B | $1.05B | $1.12B | $1.77B |
| Cost of Revenue | $0.39B | $0.67B | $0.69B | $0.64B | $0.98B |
| Gross Profit | $0.35B | $0.38B | $0.36B | $0.47B | $0.79B |
| Gross Margin %(computed) | 47.19% | 35.97% | 34.31% | 42.33% | 44.72% |
| Operating Expenses | |||||
| R&D Expenses | $0.05B | $0.07B | $0.11B | $0.19B | $0.24B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $0.24B | $0.48B | $1.09B | $0.64B | $0.45B |
| Operating Income | $0.11B | ($0.11B) | ($0.73B) | ($0.17B) | $0.34B |
| Operating Margin %(computed) | 14.83% | -10.42% | -69.23% | -15.21% | 19.25% |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.06B | $0.07B | $0.09B | $0.04B | $0.03B |
| Income Before Tax | $0.08B | ($0.14B) | ($0.73B) | ($0.22B) | $0.30B |
| Income Tax Expense | $0.03B | $0.05B | $0.03B | ($0.01B) | $0.08B |
| Net Income | $0.05B | ($0.19B) | ($0.76B) | ($0.21B) | $0.22B |
| Net Margin %(computed) | 7.08% | -18.26% | -72.48% | -18.94% | 12.38% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $0.98 | $-3.60 | $-14.85 | $-4.22 | $4.10 |
| Wtd Avg Shares | 0.05B | 0.05B | 0.05B | 0.05B | 0.05B |
| EBITDA | $0.21B | $0.05B | ($0.05B) | $0.02B | $0.50B |
| EBITDA Margin %(computed) | 28.07% | 5.12% | -4.48% | 1.40% | 28.43% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Emergent BioSolutions Inc. data
About Emergent BioSolutions Inc. (EBS) Income Statement
Emergent BioSolutions Inc. (EBS) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, EBS reported revenue of $0.74B, gross profit of $0.35B (gross margin 47.19%), and net income of $0.05B — a net profit margin of 7.08%.
Frequently asked questions
EBS · 4 questionsEmergent BioSolutions Inc. (EBS) reported revenue of $0.74B for 2025, down 28.8% year-over-year.
EBS revenueEBS salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08